KLTO
Klotho Neurosciences, Inc.
Biotechnology
Market Cap$7M
5Y Perf.-59.1%
Build Your Comparison
Side-by-side financial analysisKLTO
SAVA
Try popular comparisons:
Stock Comparison
KLTO vs SAVA
Revenue, margins, valuation, and 5-year total return — side by side.
SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$64M
5Y Perf.-52.3%
KLTO vs SAVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  KLTO |  SAVA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $7M | $64M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-11M | $-106M |
| Total Debt | $272K | $0.00 |
| Cash & Equiv. | $64K | $129M |
KLTO vs SAVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KLTO
SAVA
| Stock | Aug 24 | Mar 26 | Return |
|---|---|---|---|
| Klotho Neuroscience… (KLTO) | 100 | 40.9 | -59.1% |
| Cassava Sciences, I… (SAVA) | 100 | 47.7 | -52.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KLTO vs SAVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SAVA leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Klotho Neurosciences, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
🥇SAVA emerged as the overall leader. Track its performance:
KLTO
Klotho Neurosciences, Inc.
The Income Pick
KLTO is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.91
- Lower volatility, beta 1.91, Low D/E 22.9%, current ratio 0.13x
- Beta 1.91, current ratio 0.13x
Best for: income & stability and sleep-well-at-night
SAVA
Cassava Sciences, Inc.
The Growth Play
SAVA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 77.6%
- -38.0% 10Y total return vs KLTO's -63.0%
- -5.4% revenue growth vs KLTO's -49.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  SAVA | -5.4% revenue growth vs KLTO's -49.0% |
| Quality / Margins | SAVA | 5.4% margin vs KLTO's -14.5% |
| Stability / Safety |  KLTO | Beta 1.91 vs SAVA's 1.92 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SAVA | -37.7% vs KLTO's -81.0% |
| Efficiency (ROA) | SAVA | -75.3% ROA vs KLTO's -112.1%, ROIC -6.3% vs -242.3% |
KLTO vs SAVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSAVALAGGINGKLTO
KLTOKlotho Neurosciences,…
1leads
SAVACassava Sciences, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs KLTOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KLTO1/1
Valuation MetricsMultiples, price ratios, and targets
SAVA2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SAVA5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
SAVA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KLTO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KLTO and SAVA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | KLTOKlotho Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$8M | -$110M |
| Net IncomeAfter-tax profit | -$11M | -$106M |
| Free Cash FlowCash after capex | -$6M | -$84M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +72.9% | +62.1% |
KLTO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
SAVA leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | KLTOKlotho Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| Market CapShares × price | $7M | $64M |
| Enterprise ValueMkt cap + debt − cash | $8M | -$65M |
| Trailing P/EPrice ÷ TTM EPS | -1.19x | -2.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 6.19x | 0.42x |
| Price / FCFMarket cap ÷ FCF | — | — |
SAVA leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
SAVA leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
SAVA delivers a -95.8% return on equity — every $100 of shareholder capital generates $-96 in annual profit, vs $-114 for KLTO. On the Piotroski fundamental quality scale (0–9), KLTO scores 4/9 vs SAVA's 2/9, reflecting mixed financial health.
| Metric | KLTOKlotho Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| ROE (TTM)Return on equity | -113.7% | -95.8% |
| ROA (TTM)Return on assets | -112.1% | -75.3% |
| ROICReturn on invested capital | -2.4% | -6.3% |
| ROCEReturn on capital employed | -6.2% | -99.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.23x | — |
| Net DebtTotal debt minus cash | $208,012 | -$129M |
| Cash & Equiv.Liquid assets | $63,741 | $129M |
| Total DebtShort + long-term debt | $271,753 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -1.98x | — |
SAVA leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
SAVA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KLTO five years ago would be worth $3,699 today (with dividends reinvested), compared to $1,219 for SAVA. Over the past 12 months, SAVA leads with a -37.7% total return vs KLTO's -81.0%. The 3-year compound annual growth rate (CAGR) favors SAVA at -27.9% vs KLTO's -28.2% — a key indicator of consistent wealth creation.
| Metric | KLTOKlotho Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| YTD ReturnYear-to-date | +19.1% | -36.8% |
| 1-Year ReturnPast 12 months | -81.0% | -37.7% |
| 3-Year ReturnCumulative with dividends | -63.0% | -62.5% |
| 5-Year ReturnCumulative with dividends | -63.0% | -87.8% |
| 10-Year ReturnCumulative with dividends | -63.0% | -38.0% |
| CAGR (3Y)Annualised 3-year return | -28.2% | -27.9% |
SAVA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KLTO and SAVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
KLTO is the less volatile stock with a 1.91 beta — it tends to amplify market swings less than SAVA's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SAVA currently trades 26.5% from its 52-week high vs KLTO's 15.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KLTOKlotho Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 1.92x |
| 52-Week HighHighest price in past year | $2.45 | $4.98 |
| 52-Week LowLowest price in past year | $0.21 | $1.27 |
| % of 52W HighCurrent price vs 52-week peak | +15.6% | +26.5% |
| RSI (14)Momentum oscillator 0–100 | 61.9 | 42.7 |
| Avg Volume (50D)Average daily shares traded | 95K | 134K |
Evenly matched — KLTO and SAVA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | KLTOKlotho Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SAVA leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). KLTO leads in 1 (Income & Cash Flow). 1 tied.
Best OverallCassava Sciences, Inc. (SAVA)Leads 3 of 6 categories
Loading custom metrics...
KLTO vs SAVA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is KLTO or SAVA a better buy right now?
Analysts rate Cassava Sciences, Inc.
(SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KLTO or SAVA?
Over the past 5 years, Klotho Neurosciences, Inc.
(KLTO) delivered a total return of -63. 0%, compared to -87. 8% for Cassava Sciences, Inc. (SAVA). Over 10 years, the gap is even starker: SAVA returned -38. 0% versus KLTO's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KLTO or SAVA?
By beta (market sensitivity over 5 years), Klotho Neurosciences, Inc.
(KLTO) is the lower-risk stock at 1. 91β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately 1% more volatile than KLTO relative to the S&P 500.
04Which has better profit margins — KLTO or SAVA?
Klotho Neurosciences, Inc.
(KLTO) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Cassava Sciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KLTO leads at 0. 0% versus 0. 0% for SAVA. At the gross margin level — before operating expenses — KLTO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — KLTO or SAVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is KLTO or SAVA better for a retirement portfolio?
For long-horizon retirement investors, Cassava Sciences, Inc.
(SAVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Klotho Neurosciences, Inc. (KLTO) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SAVA: -38. 0%, KLTO: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between KLTO and SAVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.